Research shows the Siyakhula Study has enrolled 315 mother and baby pairs, 152 with maternal HIV and 163 without, to test whether HIV and HIV medicines during pregnancy affect infant growth, immunity, and brain development. According to research reviewed by Gram, final results have not yet been published.

Researchers have built a large study called the Siyakhula Study to answer a question many families care about: how does a mother’s HIV status and her HIV medicines during pregnancy affect babies who are not infected? According to research reviewed by Gram, the study enrolled 315 pregnant women between 2018 and 2021, with 152 living with HIV and 163 without. The team followed each mother and baby pair for up to two years after birth. They collected blood, breast milk, stool, and placenta samples, measured babies’ growth, and planned tests of thinking and brain development. This paper describes the study’s design and the large library of samples and data it has created. It does not yet report final results. Its value is in giving scientists a detailed, shared resource to study how early life conditions shape healthy growth and immunity.

Key Statistics

A 2026 cohort profile published in PLOS ONE described the Siyakhula Study, which enrolled 315 pregnant women between January 2018 and January 2021, including 152 living with HIV and 163 without HIV.

The Siyakhula Study followed infants for 24 months, measuring their growth at 6, 10, and 14 weeks and again at 6, 12, and 24 months after birth.

The Quick Take

  • What they studied: How a mother’s HIV status and HIV medicines during pregnancy may affect a baby’s growth, immune system, and brain development, even when the baby is not infected with HIV.
  • Who participated: 315 pregnant women aged 18 or older with a single baby, recruited early in pregnancy. Of these, 152 were living with HIV and 163 were not. Their babies were followed for two years after birth.
  • Key finding: This paper describes the study setup rather than reporting final results. The study enrolled 315 mother and baby pairs and collected a wide range of health information and samples, creating a resource for future research.
  • What it means for you: This paper does not yet show whether HIV medicines help or harm babies. It lays the groundwork for future findings. If you are pregnant and living with HIV, talk with your healthcare provider about your treatment and your baby’s care.

The Research Details

This is a cohort profile, a paper that describes how a long-term study was designed and what information it has gathered. The Siyakhula Study is a prospective cohort, meaning researchers followed the same group of people forward in time. Pregnant women joined between January 2018 and January 2021 and were followed through their pregnancy.

After delivery, mothers could continue into a postpartum phase lasting 24 months. During pregnancy, researchers gathered clinical records, HIV status, body measurements, family background, diet information, body composition scans, and blood and vaginal swab samples. At birth, they collected umbilical cord blood and placenta samples.

After birth, researchers collected breast milk, stool, and blood samples. Babies were measured at 6, 10, and 14 weeks, and again at 6, 12, and 24 months. Later visits included tests of development.

Following the same mothers and babies over time lets researchers see how early conditions relate to later health. Because the study collects many kinds of information from the same people, scientists can look at growth, immunity, nutrition, and brain development together. A shared biobank of samples also means future researchers can test new ideas without recruiting a new group.

The study has a clear design, a defined starting group, and planned follow-up visits, all of which are strengths. Enrolling mothers both with and without HIV allows comparisons between groups. The paper also reports a large collection of data and samples, which increases its usefulness. Readers should keep in mind that a cohort profile describes a study rather than proving a result, so its reliability will be judged by the findings that come later.

What the Results Show

This paper does not report the main outcomes of the Siyakhula Study. Instead, it explains who was enrolled, how data were collected, and what samples are available. The study enrolled 315 pregnant women, with 152 living with HIV and 163 without HIV, which provides a balanced comparison group.

The researchers gathered a wide range of information about each mother and baby. This includes clinical records, nutrition details, body measurements, immune and metabolic markers, and developmental assessments. Together, these data are meant to show how a baby’s growth and development are shaped from pregnancy onward.

The team describes the biorepository, which holds maternal and infant samples such as blood, placenta, cord blood, breast milk, and stool. Scientists can use these materials for future research on how the body’s chemistry relates to health.

The authors state that a future goal is to identify patterns in immune and metabolic markers linked to better or poorer growth and brain development during the first two years of life. Those findings have not yet been reported in this paper.

The paper’s most useful content for readers is its description of how the study is organized. The schedule of growth checks at 6, 10, and 14 weeks and at 6, 12, and 24 months shows that researchers are tracking babies closely during the period when growth and immunity change quickly. Neurodevelopmental assessments at later visits will help researchers link early life conditions with thinking and brain development.

The study also includes a large set of biological samples, which can support many future projects. Because the same samples and data are linked to each participant, researchers can test ideas that were not planned when the study began.

Many studies have looked at how HIV and HIV medicines affect pregnancy and infant health. Some research has raised questions about growth and development in babies who are exposed to these medicines but are not infected. The Siyakhula Study adds a detailed, multi-part approach that measures immunity, nutrition, body chemistry, and development together. This matches a broader trend in nutrition and child health research toward linking many types of data from the same people over time.

Because this is a description of a study rather than a report of results, it cannot answer whether HIV medicines help or harm babies. The findings will depend on the analyses that follow. The study’s participants were recruited under specific conditions, so results may not apply equally to all pregnant women or all settings. Following people over two years also means some participants may leave the study or miss visits, which can affect the data. Finally, collecting many measurements is valuable, but it does not by itself prove cause and effect.

The Bottom Line

No clinical recommendations can be made from this paper alone, because it does not report outcomes. Confidence that the study is well organized is high, since its design is clearly described. Confidence in any specific health effect is currently low, because results have not yet been published. Pregnant people living with HIV should continue to follow their healthcare team’s advice on treatment and monitoring.

Researchers studying maternal health, infant growth, and HIV should pay close attention, since the study offers a detailed resource. Healthcare workers who care for pregnant women and infants may also find it useful. Pregnant people and families may find it reassuring that research is being done, but this paper does not change any individual care plan. Readers who are not pregnant or caring for infants will likely find less direct relevance.

The study followed mothers from pregnancy and babies for 24 months after birth, so the full data collection period spans about three years per participant. Enrollment took place from 2018 to 2021. Results from the analyses described as future work will likely take additional time to appear in published research.

Frequently Asked Questions

What is the Siyakhula Study about?

The Siyakhula Study is a long-term cohort that followed 315 pregnant women and their babies. It examines how maternal HIV status and HIV medicines may influence infant growth, immunity, nutrition, and brain development, whether or not the baby has HIV.

How many mothers and babies were included in the Siyakhula Study?

The study recruited 315 pregnant women between January 2018 and January 2021. Of these, 152 were living with HIV and 163 were not. Mothers were followed through pregnancy, and babies were tracked for 24 months after birth.

Does the Siyakhula Study show that HIV medicines harm babies?

The Siyakhula Study has not yet reported its main outcomes. The published cohort profile describes the study design, participants, and collected samples. Conclusions about effects on infant health will depend on future analyses.

What did researchers measure in the Siyakhula Study?

Researchers measured infant growth at several ages, collected blood, breast milk, stool, and placenta samples, and gathered nutrition and clinical data. Neurodevelopmental assessments were planned for later visits to study thinking and brain development.

Want to Apply This Research?

  • If you are pregnant or caring for an infant, log your baby’s weight, length, and head circumference at each well-child visit, and note the date. Track feeding type and volume each week to see how nutrition relates to growth patterns.
  • Use the app to set reminders for prenatal visits, infant checkups, and any medication schedules your provider recommends. Keep a simple daily note on feeding, sleep, and milestones so you can share clear information with your healthcare team.
  • Create a long-term record for your child that includes growth measurements, feeding changes, developmental milestones, and any health concerns. Review this record at each checkup and bring it to your provider to discuss trends rather than single readings.

This article summarizes a cohort profile that describes study design and available data, not final clinical results. It is for general information only and is not medical advice. Pregnant people living with HIV and parents of infants should consult their healthcare providers before making any decisions about treatment, medication, or infant care.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Cohort profile: Assessment of factors impacting on foetal and infant immunity, growth, and neurodevelopment in HIV and antiretroviral drug exposed uninfected children: The Siyakhula Study. , PloS one (2026). PubMed 43038208 | DOI
Topics
Siyakhula Study HIV exposed uninfected children antiretroviral medicines pregnancy infant growth infant immunity child neurodevelopment maternal nutrition birth cohort study